Reference : Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to an...
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/203963
Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients.
English
Moller, Ingrid [> >]
Gharbi, Myriam [> >]
Martinez Serrano, Helena [> >]
Herrero Barbero, Marta [> >]
Verges Milano, Josep [> >]
Henrotin, Yves mailto [Université de Liège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.) >]
2016
BMC Musculoskeletal Disorders
17
1
416
Yes (verified by ORBi)
International
1471-2474
England
[en] Biomarkers ; Cartilage metabolism ; Chondroitin sulfate ; Osteoarthritis ; Pain
[en] BACKGROUND: The aim of this study was to investigate the effects of chondroitin sulfate (CS) on the serum levels of Coll2-1 in patients with knee OA. METHODS: Seventy two patients with unilateral symptomatic knee OA were involved in a post-authorization open-label study evaluating CS (800 mg/day). The primary outcome was the % relative change in serum Coll2-1 (sColl2-1). The secondary outcomes were the evaluation of pain (VAS) and function (Lequesne's Index). Responders and non-responders were classified according to OMERACT-OARSI recommendations. Finally, an original cut-off method was applied to categorize patients and interpret individual variations in serum levels of Coll2-1. RESULTS: Patients showed no difference in the sColl2-1 levels at baseline. When considering responders and non-responders from the ITT population, a significant difference was found for Coll2-1 at 3 months (p = 0.030) and 6 months (p = 0.038). A decrease in pain (VAS) and an improvement in function (LI) were recorded throughout the visits (p < 0.01). Considering an intra-batch cut-off of 21 %, CS decreased Coll2-1 serum levels between baseline and 1-month visit compared to the value of Coll2-1 before treatment (screening visit) which can be interpreted as a drastic reduction of the proportion of patients with an increase of Coll2-1 over 21 % (reduction from 13 to 3 %). It also consisted in a more important proportion of patients with a decrease in Coll2-1 (from 5 to 10 %). CONCLUSION: This study proposes a new approach for the analysis and the interpretation of the individual variation in biomarker levels and introduces the notion of metabolic responders. TRIAL REGISTRATION: ID ISRCTN63795830 . The trial was retrospectively registered on 2 October, 2015.
http://hdl.handle.net/2268/203963
10.1186/s12891-016-1268-4

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
12891_2016_Article_1268.pdfPublisher postprint471.28 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.